Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 5.3% Following Insider Buying Activity

Pulse Biosciences, Inc. (NASDAQ:PLSE) rose 5.3% on Tuesday after an insider bought additional shares in the company. The stock traded as high as $20.54 and last traded at $20.18. Approximately 20,155 shares were traded during trading, a decline of 90% from the average daily volume of 200,547 shares. The stock had previously closed at $19.17.

Specifically, Director Robert W. Duggan bought 55,256 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were acquired at an average price of $17.18 per share, with a total value of $949,298.08. Following the completion of the transaction, the director now owns 42,328,717 shares in the company, valued at $727,207,358.06. The trade was a 0.13 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Robert W. Duggan purchased 56,054 shares of the stock in a transaction on Wednesday, December 11th. The shares were bought at an average cost of $17.35 per share, for a total transaction of $972,536.90. Following the transaction, the director now directly owns 42,228,057 shares in the company, valued at approximately $732,656,788.95. The trade was a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research note on Thursday, December 12th.

Pulse Biosciences Trading Down 7.3 %

The firm has a fifty day moving average price of $17.85 and a 200-day moving average price of $16.56.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same period last year, the business posted ($0.19) EPS.

Institutional Trading of Pulse Biosciences

A number of hedge funds have recently added to or reduced their stakes in PLSE. Rhumbline Advisers lifted its stake in shares of Pulse Biosciences by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after acquiring an additional 1,608 shares during the last quarter. Quest Partners LLC bought a new stake in Pulse Biosciences during the 2nd quarter worth approximately $91,000. Bank of New York Mellon Corp increased its position in Pulse Biosciences by 23.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after acquiring an additional 9,639 shares during the period. Creative Planning raised its stake in shares of Pulse Biosciences by 113.9% during the third quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after acquiring an additional 11,667 shares during the last quarter. Finally, Franklin Resources Inc. acquired a new stake in Pulse Biosciences in the third quarter valued at $378,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.